Cardio-active with taurine tablets N60 Evalar

International nonproprietary or group name: taurine

Dosage form: tablets.

Composition per tablet

Active ingredient: taurine - 500 mg.

Excipients: povidone - 57.0 mg, microcrystalline cellulose - 18.0 mg, sodium croscarmellose - 17.2 mg, calcium stearate - 4.8 mg, colloidal silicon dioxide - 3.0 mg.

Description: white or almost white tablets, round, flat-cylindrical with a risk and a chamfer.

Pharmacotherapeutic group: other agents for the treatment of gastrointestinal tract diseases and metabolic disorders; amino acids and their derivatives.

Pharmacological properties

Pharmacodynamics

Taurine is a natural product of the metabolism of sulfur-containing amino acids: cysteine, cysteamine, methionine. Taurine has osmoregulatory and membrane-protective properties, has a positive effect on the phospholipid composition of cell membranes, and normalizes the exchange of calcium and potassium ions in cells. Taurine has been shown to have inhibitory neurotransmitter properties, it has an anti-stress effect, can regulate the release of gamma-aminobutyric acid (GABA), adrenaline, prolactin and other hormones, and regulate responses to them. Participating in the synthesis of respiratory chain proteins in mitochondria, taurine regulates oxidative processes and exhibits antioxidant properties; affects enzymes such as cytochromes involved in the metabolism of various xenobiotics.

Taurine improves metabolic processes in the heart, liver and other organs and tissues. In chronic diffuse liver diseases, taurine increases blood flow and reduces the severity of cytolysis.

Treatment with CardioActive® Taurine in cardiovascular insufficiency (CVI) leads to a decrease in congestion in the small and large circles of blood circulation: intracardiac diastolic pressure decreases, myocardial contractility increases (maximum contraction and relaxation velocity, contractility and relaxation indices). The drug moderately reduces blood pressure (BP) in patients with arterial hypertension and has virtually no effect on BP in patients with cardiovascular insufficiency with low BP.

CardioActive® Taurine reduces side effects that occur with an overdose of cardiac glycosides and "slow" calcium channel blockers; reduces the hepatotoxicity of antifungal drugs. Increases performance under heavy physical exertion.

In diabetes mellitus, approximately 2 weeks after the start of taking CardioActive® Taurine, the concentration of glucose in the blood decreases. A significant decrease in triglyceride concentrations, to a lesser extent – ​​cholesterol concentrations, and a decrease in the atherogenicity of plasma lipids were also noted. With long-term use of the drug (about 6 months), an improvement in the microcirculatory blood flow of the eye was noted.

Pharmacokinetics

After a single oral administration of 500 mg of CardioActive® Taurine, the active substance taurine is detected in the blood after 15–20 minutes, reaching a maximum after 1.5–2 hours. The drug is completely eliminated after 24 hours.

Indications for use

diabetes mellitus type 2, including with moderate hypercholesterolemia;

diabetes mellitus type 1;

cardiovascular insufficiency of various etiologies;

intoxication caused by cardiac glycosides;

as a hepatoprotector in patients taking antifungal drugs.

Contraindications

Hypersensitivity to taurine or any of the excipients of the drug. Age under 18 years (efficacy and safety have not been established).

If you have any of the listed conditions, be sure to consult a doctor before taking the drug.

Use during pregnancy and breastfeeding

It is not recommended to use CardioActive® Taurine during pregnancy and breastfeeding due to the lack of sufficient experience of clinical use in this category of patients.

Method of administration and dosage

The drug is taken orally, 20 minutes before meals.

The tablet can be divided into 2 equal parts.

For type 2 diabetes mellitus, including those with moderate hypercholesterolemia: 500 mg (1 tablet) 2 times a day in monotherapy or in combination with other hypoglycemic agents for oral administration, the duration of the course is as recommended by a doctor.

For type 1 diabetes mellitus: 500 mg (1 tablet) 2 times a day in combination with insulin therapy for 3-6 months.

For cardiovascular insufficiency: 250–500 mg (1/2–1 tablet) 2 times a day, treatment course – 30 days. The dose can be increased to 2–3 g (4–6 tablets) per day.

For intoxication with cardiac glycosides: at least 750 mg (1.5 tablets) per day.

As a hepatoprotector: 500 mg (1 tablet) 2 times a day during the entire course of taking antifungal drugs.

Side effects

Immune system disorders: frequency unknown – allergic reactions.

If any of the side effects listed in the instructions worsen, or you notice any other side effects not listed in the instructions, tell your doctor.

Overdose

There is no data on overdose.

Interaction with other drugs

CardioActive® Taurine can be used with other drugs.

Taurine enhances the inotropic effect of cardiac glycosides.

Special instructions

While taking the drug, the dose of cardiac glycosides should be reduced, sometimes by 2 times, depending on the sensitivity of patients to cardiac glycosides. The same rule applies to blockers of "slow" calcium channels.

If there is no reduction or if the symptoms of the disease worsen, consult a doctor.

Do not exceed the maximum periods and recommended doses of the drug without consulting a doctor.

Influence on the ability to drive vehicles, mechanisms

The drug does not affect the performance of potentially dangerous activities that require increased concentration and speed of psychomotor reactions (driving a car and other vehicles, working with moving mechanisms, work of a dispatcher, operator, etc.).

Storage conditions

At a temperature not exceeding 25 °C.

Keep out of reach of children.

Do not use after expiration date.

Registration Certificate Holder / Manufacturer / Organization accepting claims from consumers

ZAO Evalar, Russia

Why CardioActive Taurine?

1. Highly purified taurine is used to produce the drug CardioActive Taurine, which, due to its high therapeutic activity, provides a rapid effect on the entire body at the same time.

2. Taurine is a substance related to the body, which acts on it naturally within the physiological norm, without disrupting the natural course of internal processes in the body.

3. Mono-composition: the drug contains only one active substance and does not burden the body with additional components. It is easy to include in the medication schedule.

4. Taking 2 tablets provides 250% of the recommended daily intake - 1000 mg of taurine.